ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data

Zhu, Songling; Bao, Hongxia; Zhang, Meng-Chun; Liu, Huidi; Wang, Yao; Lin, Caiji; Zhao, Xingjuan; Liu, Shu-Lin*哈尔滨医科大学
BMC CANCER2022-6-16DOI: 10.1186/s12885-022-09747-2
2被引10阅读
引用收藏
分享

摘要

Background Ovarian cancer (OC) is among the deadliest malignancies in women and the lack of appropriate markers for early diagnosis leads to poor prognosis in most cases. Previous studies have shown that KAZN is involved in multiple biological processes during development, such as cell proliferation, differentiation, and apoptosis, so defects or aberrant expression of KAZN might cause queer cell behaviors such as malignancy. Here we evaluated the KAZN expression and methylation levels for possible use as an early diagnosis marker for OC. Methods We used data from Gene Expression Omnibus (GEO) microarrays, The Cancer Genome Atlas (TCGA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) to investigate the correlations between KAZN expression and clinical characteristics of OC by comparing methylation levels of normal and OC samples. The relationships among differentially methylated sites in the KAZN gene, corresponding KAZN mRNA expression levels and prognosis were analyzed. Results KAZN was up-regulated in ovarian epithelial tumors and the expression of KAZN was correlated with the patients' survival time. KAZN CpG site cg17657618 was positively correlated with the expression of mRNA and the methylation levels were significantly differential between the group of stage "I and II" and the group of stage "III and IV". This study also presents a new method to classify tumor and normal tissue in OC using DNA methylation pattern in the KAZN gene body region. Conclusions KAZN was involved in ovarian cancer pathogenesis. Our results demonstrate a new direction for ovarian cancer research and provide a potential diagnostic biomarker as well as a novel therapeutic target for clinical application.

学科与关键词

关键词
KAZNOvarian cancerMethylationBioinformaticsSurvival
相关
加载中…
  • Integrated miRNA-mRNA Expression Profiles Revealing Key Molecules in Ovarian Cancer Based on Bioinformatics Analysis
    Li, Chao*; Hong, Zhantong; Ou, Miaoling; Zhu, Xiaodan; Zhang, Linghua; Yang, XingkunBiomed Research International, 2021, 2021: 6673655.被引 3
  • Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA
    Chen, Lu; Ma, Rong; Luo, Chang; Xie, Qin; Ning, Xin; Sun, Kaidi; Meng, Fanling*; Zhou, Meng*; Sun, Jie*Translational Research, 2023, 262: 12-24.被引 1
  • Epigenetic and immunohistochemical characterization of the Clusterin gene in ovarian tumors
    Yang Guofen; Zhang Haihong; Liu Yu; Zhou Juan; He Weipeng; Quick Charles M; Xie Dan; Smoller Bruce R; Fan Chun Yang*Archives of Gynecology and Obstetrics, 2013, 287(5): 989-995.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2022-06-16
卷期
第 22 卷, 第 1 期
页码
662
DOI
10.1186/s12885-022-09747-2
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [NSFC81871623, 82020108022]

作者

  • Z

    Zhu, Songling (第一作者)

    harbin med univ

  • B

    Bao, Hongxia

    harbin med univ

查看全部 8 位作者收起作者
  • Z

    Zhang, Meng-Chun

    harbin med univ

  • L

    Liu, Huidi

    harbin med univ

  • W

    Wang, Yao

    harbin med univ

  • L

    Lin, Caiji

    harbin med univ

  • Z

    Zhao, Xingjuan

    2 · harbin med univ

  • L

    Liu, Shu-Lin (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417